In the News

Cardiovascular event rates similar between once-weekly exenatide and placebo in patients with type 2 diabetes

A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo.

Dapagliflozin appears effective as adjunct therapy in patients with type 1 diabetes

Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.

Insulin pumps reduced ketoacidosis, hypoglycemia in young patients with type 1 diabetes

The results provide further evidence that insulin pump therapy is safe and effective, even in routine diabetes care for unselected patients, according to the study authors.

MKSAP quiz: Intensifying treatment

This month's quiz asks readers to evaluate a 64-year-old man whose HbA1c is not at goal despite taking metformin and glipizide.

Spotlight on second-line therapies

Two recent studies considered whether initiation of second-line therapies in patients already taking metformin for type 2 diabetes occurs too soon or too late.

CGM system approved for use without finger sticks

A continuous glucose monitoring (CGM) system was approved and some infusion sets were recalled, the FDA recently announced.

Gastric bypass benefits persist over long-term follow-up, study finds

At 12 years, patients who underwent Roux-en-Y gastric bypass had significantly greater weight loss and lower risk of diabetes than those who didn't receive surgery.